BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:de4475083b4f55b4202dddd71c56dbc6
ORGANIZER:registration@iasusa.org
DTSTAMP:20261027T212047Z
LOCATION:1710 Orrington Ave\, Evanston\, Illinois\, 60201\, United States
SUMMARY:Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis\, Antiretrovirals\, and Other Selected Issues in HIV Disease Management
DESCRIPTION:March 27\, 2020: Chicago Course Postponed\nAs you know\, many agencies\, institutions\, and governments have banned travel and attending meetings\, and many infectious disease clinicians are urgently needed to care for patients with COVID-19. In addition\, the Hilton Orrington/Evanston Hotel has informed us that it will be closed through May. Therefore\, the May 21\, 2020\, Annual Update on HIV Management in Chicago\, IL\, has been postponed.\nOnce we determine the new date for the in-person course\, your registration will automatically transfer. We will send an update with more information on Monday. Please check your email and the IAS–USA website regularly for updates.\nWe thank you for your patience\, understanding\, and support during this uncertain time. And above all\, we hope you\, your patients\, your colleagues\, and your community stay safe.\n\n\nAgenda\nView the agenda\n\n\nAssessment of Needs\nRapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.\nLearning Objectives\nAfter participating in the activity\, learners will be better able to:\n\n 	Describe the most current data on currently available and investigational new drugs\, formulations\, and strategies\n 	Identify situations in which the choice of antiretroviral regimens should consider particular clinical circumstances\, such as comorbid conditions\, coinfections\, pregnancy\, and issues in older patients\n 	Describe the research around the role of therapeutic HIV vaccines and broadly neutralizing antibodies\n 	Initiate and monitor HIV prevention intervention strategies\, including the use of preexposure prophylaxis (PrEP)\, in individuals at risk for HIV infection\n 	Identify chronic opioid dependent patients and initiate opioid substitution therapy as appropriate\n 	Apply newly available data to provide specific immunization guidance based on an individual’s immunologic status and assessed risk\n\nConflicts of Interest\nIn the interest of maintaining the independence of its CME activities\, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME)\, the IAS–USA requires all persons with control of content (eg\, faculty\, IAS–USA Board members\, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.\n\nThe ACCME defines a commercial interest as “any entity producing\, marketing\, re-selling\, or distributing health care goods or services consumed by\, or used on\, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned\, or controlled by\, an ACCME-defined commercial interest.”\nRegistration\nWho Should Attend\nThis course is designed for physicians who are actively involved in the medical care of people with HIV infection and:\n\n 	Have a solid\, working knowledge of HIV disease management\n 	Provide comprehensive or specialty care for patients with HIV infection\n 	Are currently active in HIV research\n\nThis activity is also relevant to nurse practitioners\, registered nurses\, physician assistants\, registered pharmacists\, and other health professionals.\n\nRepresentatives and employees of commercial companies (eg\, pharmaceutical\, diagnostic\, medical products\, advertising\, insurance\, investment\, and communications firms) must contact the IAS–USA regarding registration procedures.\nCancellation Policy\nCancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably\, any cancellation requests received within a week before the course will not be eligible for the partial refund.\n\n\n\n\nContinuing Education Credits\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nABIM MOC Points\nSuccessful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 6.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit\nNursing Credits\nThis activity is eligible for ANCC credit\; see the final CNE activity announcement for specific details.\nPharmacy Credits\nThis activity is eligible for ACPE credit\; see the final CPE activity announcement for specific details.\n\n\n\n\nGrant Support\n\n\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from commercial companies. Per IAS–USA policy\, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees\, not with grant support money. Generous support for this activity has been received from the following contributors.\n\nPLATINUM SUPPORTERS\n\nGilead Sciences\, Inc\nMerck &amp\; Co\, Inc\nViiV Healthcare\n\nSILVER SUPPORTER\n\nJanssen Therapeutics\n\n\n\nPhysician Payment Sunshine Act (“Sunshine Act” or “Open Payment”)\nIn 2014\, the Physician Payment Sunshine Act (“Sunshine Act” or “Open Payments”)\, a provision of the Affordable Care Act\, was developed. According to the Centers for Medicare and Medicaid Services (CMS): “Open Payments is a national disclosure program that promotes transparency by publishing the financial relationships between the medical industry and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS.” Until recently\, CME activities that receive commercial support have been exempt from reporting payments for goods such as hosted meals. Attendee registration fees are used for all food and beverage expenses provided by IAS–USA at the activity.
STATUS:CONFIRMED
CATEGORIES:
URL;VALUE=URI:https://www.iasusa.org/events/2020-spring-chicago/
DTSTART:20200521T153000Z
DTEND:20200521T230000Z
END:VEVENT
END:VCALENDAR